Last Price$86.0(2.7%)
Market Cap$34.9B
P/EBITDA LTM
31.5x
5Y avg
69.7x
Medical - Devices industry
median
(1.0x)
Stock quality & Intrinsic value
7/10
(0.5%) overvalued
DexCom, Inc. P/EBITDA LTM
Annual
Quarterly
Daily
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/EBITDA LTM | (15.3x) | (5.7x) | (5.7x) | (8.2x) | (7.8x) | (15.2x) | (15.7x) | (16.9x) | (89.5x) | (242.2x) | (142.6x) | (121.7x) | (120.5x) | 102.0x | (279.7x) | 91.5x | 113.6x | 100.9x | 60.5x | 31.5x |
Overvalued or undervalued?
Check the intrinsic value for DXCM
and see if it's the right time to invest.
DexCom, Inc. (DXCM) P/EBITDA LTM comparison analysis
General
LTM P/EBITDA LTM
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
DexCom, Inc.DXCM
38.2x
11.3%
(1.4%)
14.3%
Median Peer Set
23.0x
4.1%
126.3%
11.8%
Insulet CorporationPODD
47.1x
30.0%
4,364.6%
12.2%
Boston Scientific CorporationBSX
40.0x
17.6%
16.7%
11.1%
Stryker CorporationSYK
33.6x
10.2%
(5.8%)
13.2%
Edwards Lifesciences CorporationEW
25.5x
(9.4%)
202.2%
76.7%
Koninklijke Philips N.V.PHG
23.6x
(0.8%)
118.1%
(3.9%)
Abbott LaboratoriesABT
22.3x
4.6%
134.5%
31.9%
Align Technology, Inc.ALGN
18.1x
3.4%
26.0%
11.5%
STERIS plcSTE
17.9x
3.6%
257.9%
7.4%
Medtronic plcMDT
16.4x
3.6%
(2.1%)
11.4%
Zimmer Biomet Holdings, Inc.ZBH
11.9x
6.5%
253.2%
13.8%
DXCM key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 0.0 0.0% | 2.2 0.0% | 4.6 113.2% | 9.8 112.6% | 29.7 201.8% | 48.6 63.8% | 76.3 56.8% | 99.9 31.0% | 160.0 60.2% | 259.2 62.0% | 402.0 55.1% | 573.3 42.6% | 718.5 25.3% | 1,031.6 43.6% | 1,476.0 43.1% | 1,926.7 30.5% | 2,448.5 27.1% | 2,909.8 18.8% | 3,622.3 24.5% | 4,033.0 11.3% |
| Cost of Goods Sold (COGS) | 0.0 | 11.0 | 12.7 | 15.4 | 26.0 | 30.2 | 40.4 | 53.3 | 59.9 | 82.9 | 123.6 | 194.9 | 226.4 | 367.7 | 544.5 | 646.6 | 768.0 | 1,026.7 | 1,333.4 | 1,567.3 |
% margin | 0.0 0.0% | (8.8) (405.1%) | (8.1) (175.3%) | (5.5) (56.2%) | 3.7 12.3% | 18.4 37.9% | 35.8 47.0% | 46.6 46.6% | 100.1 62.6% | 176.3 68.0% | 278.4 69.3% | 378.4 66.0% | 492.1 68.5% | 663.9 64.4% | 931.5 63.1% | 1,280.1 66.4% | 1,680.5 68.6% | 1,883.1 64.7% | 2,288.9 63.2% | 2,465.7 61.1% |
| Operating Expenses | 32.4 | 40.5 | 38.6 | 47.3 | 49.5 | 63.7 | 80.7 | 102.3 | 129.0 | 197.8 | 335.5 | 442.3 | 534.6 | 850.2 | 789.2 | 980.6 | 1,414.7 | 1,491.9 | 1,691.2 | 1,865.7 |
| Research & Development Expenses (R&D) | 26.8 | 19.4 | 16.1 | 19.6 | 14.3 | 23.2 | 30.7 | 39.5 | 44.8 | 69.4 | 137.5 | 156.1 | 185.4 | 417.4 | 273.5 | 359.9 | 604.2 | 484.2 | 505.8 | 552.4 |
| Selling, General & Administrative Expenses (SG&A) | 5.7 | 21.1 | 22.4 | 27.7 | 35.2 | 40.5 | 49.9 | 62.8 | 84.2 | 128.4 | 198.0 | 286.2 | 349.2 | 432.8 | 515.7 | 620.7 | 810.5 | 1,000.2 | 1,185.4 | 1,285.8 |
% margin | (32.4) 0.0% | (49.3) (2,273.0%) | (46.7) (1,008.8%) | (52.8) (537.0%) | (45.8) (154.4%) | (45.3) (93.1%) | (44.8) (58.8%) | (55.7) (55.8%) | (28.9) (18.1%) | (21.5) (8.3%) | (57.1) (14.2%) | (63.9) (11.1%) | (42.5) (5.9%) | (186.3) (18.1%) | 142.3 9.6% | 299.5 15.5% | 175.4 7.2% | 391.2 13.4% | 597.7 16.5% | 600.0 14.9% |
| Interest Income | 0.0 | 0.0 | 0.0 | 1.2 | 0.4 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.4 | 3.3 | 2.4 | 26.4 | 16.1 | 1.7 | 18.0 | 135.0 | 0.0 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 7.3 | 8.0 | 1.5 | 0.0 | 0.2 | 0.9 | 0.8 | 0.4 | 0.7 | 12.8 | 22.7 | 60.3 | 84.7 | 102.0 | 18.6 | 20.3 | 0.0 |
| Pre-tax Income | (30,889.7) | (46.6) | (45.9) | (55.2) | (53.5) | (55.2) | (44.7) | (55.8) | (29.8) | (22.3) | (57.5) | (64.9) | (48.6) | (126.5) | 104.2 | 225.0 | 173.9 | 390.8 | 710.4 | 709.0 |
% effective tax rate | (30,858.9) 99.9% | 0.0 (0.0%) | 0.0 0.0% | 2.4 (4.3%) | 0.0 0.0% | 9.9 (17.9%) | (0.1) 0.2% | (1.3) 2.3% | 0.0 0.0% | 0.1 (0.4%) | 0.1 (0.2%) | 0.7 (1.1%) | 1.6 (3.3%) | 0.6 (0.5%) | 3.1 3.0% | (268.6) (119.4%) | 19.2 11.0% | 49.6 12.7% | 168.9 23.8% | 132.8 18.7% |
% margin | (30.8) 0.0% | (46.6) (2,147.6%) | (45.9) (991.5%) | (55.2) (560.9%) | (53.5) (180.3%) | (55.2) (113.4%) | (44.7) (58.7%) | (54.5) (54.6%) | (29.8) (18.6%) | (22.4) (8.6%) | (57.6) (14.3%) | (65.6) (11.4%) | (50.2) (7.0%) | (127.1) (12.3%) | 101.1 6.8% | 493.6 25.6% | 154.7 6.3% | 341.2 11.7% | 541.5 14.9% | 576.2 14.3% |
| EPS | (0.41) | (0.43) | (0.41) | (0.47) | (0.30) | (0.24) | (0.17) | (0.20) | (0.10) | (0.07) | (0.18) | (0.20) | (0.15) | (0.36) | 0.28 | 1.31 | 0.40 | 0.88 | 1.44 | 1.42 |
| Diluted EPS | (0.41) | (0.43) | (0.41) | (0.47) | (0.30) | (0.24) | (0.17) | (0.20) | (0.10) | (0.07) | (0.18) | (0.20) | (0.15) | (0.36) | 0.27 | 1.27 | 0.36 | 0.80 | 1.30 | 1.40 |
% margin | (29.7) 0.0% | (46.6) (2,148.7%) | (43.3) (936.8%) | (49.8) (506.1%) | (43.1) (145.2%) | (51.2) (105.3%) | (41.0) (53.7%) | (49.0) (49.0%) | (21.9) (13.7%) | (13.1) (5.1%) | (46.3) (11.5%) | (49.2) (8.6%) | (19.7) (2.7%) | (74.7) (7.2%) | 213.2 14.4% | 376.8 19.6% | 377.5 15.4% | 565.3 19.4% | 916.7 25.3% | 840.7 20.8% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is DexCom, Inc.'s P/EBITDA LTM?
As of today, Microsoft Corp's last 12-month P/EBITDA LTM is 31.5x, based on the financial report for Dec 30, 2024 (Q4’2024). The average annual P/EBITDA LTM for DexCom, Inc. have been 79.0x over the past three years, and 73.1x over the past five years.
2) Is DexCom, Inc.'s P/EBITDA LTM Good?
As of today, DexCom, Inc.'s P/EBITDA LTM is 31.5x, which is higher than industry median of (1.0x). It indicates that DexCom, Inc.'s P/EBITDA LTM is Bad.